Prediction: 1 Value Stock That Will Be Worth More Than Palantir by the End of 2026

The article contrasts Palantir's (PLTR) soaring market capitalization, reaching $450 billion on strong AI-driven revenue growth and expanding operating margins, with its extreme valuation (forward P/E of 292) raising concerns about an AI bubble. Conversely, UnitedHealth (UNH) is presented as a potential value opportunity, despite current headwinds from rising medical costs and a DOJ investigation into Medicare Advantage. UnitedHealth's management has raised its 2025 earnings outlook and anticipates Optum segment margin improvement by 2027, with its current valuation of 21x 2026 earnings suggesting significant upside potential and a market cap exceeding $400 billion.

Analysis

Palantir (PLTR) has demonstrated robust financial performance, with Q2 revenue climbing 48% year-over-year to exceed $1 billion and operating margins expanding to 46%. This growth is significantly driven by its Artificial Intelligence Platform (AIP) and a substantial $10 billion U.S. Army contract. Its market capitalization has surged to $450 billion, leading to an extreme forward P/E ratio of approximately 292 and a price-to-sales ratio over 100.

These elevated valuations raise concerns about an "AI bubble," with the stock's current price potentially detached from business reality. Wall Street analysts largely rate PLTR as a "hold" or "sell," with a median price target of $165 per share, implying a market cap of $391 billion, below its current level. This suggests significant downside risk if the AI trend moderates or valuation multiples contract.

Conversely, UnitedHealth (UNH) presents a potential value opportunity despite facing headwinds from rising medical costs, increased utilization, and a Department of Justice investigation. Management has proactively addressed these challenges by raising the low end of its 2025 earnings outlook by $0.25 per share and anticipates improved Optum segment profit margins from 2027.

The stock currently trades at approximately 21 times 2026 earnings expectations, below its five-year average. This valuation, coupled with management's updated guidance, suggests potential for multiple expansion if regulatory clarity emerges or operational improvements materialize, potentially leading to a valuation exceeding $400 billion by next year.

Key Decisions for Investors

• Investors should exercise extreme caution with Palantir (PLTR) due to its exceptionally high valuation metrics and the prevailing "AI bubble" concerns, despite strong recent revenue growth.
• Consider UnitedHealth (UNH) as a potential value opportunity, closely monitoring developments regarding its DOJ investigation and the successful execution of its Medicare Advantage remediation plan.
• Rebalance portfolios by potentially reducing exposure to high-P/E growth stocks and increasing allocation to value-oriented companies like UNH, particularly as its management guidance suggests future margin expansion and valuation upside.